PD41 - Risk factors for side effects during venom immunotherapy in children with hymenoptera venom allergy

Results We enrolled 45 children with a mean ((± standart deviation) age of 10.0 ± 3.4 years. VIT with wasp venom was initiated in 39 patients (87%) and with honeybee venom in 6 patients (13%). Seventeen patients (37.8%) had encountered lokal or systemic side effects during VIT. Side effects were present in 41 out of 1448 injections (2.8%). There was no significant difference at sBT levels of children with (4.3 μg/L [3.7-6.3]) or without (4.2 μg/L [3.1-4.7]) side effects (p=0.303). Multivariate logistic regression analysis revealed presence of asthma (odds ratio; [95% confidence interval] (14.2 [2.0–123.5]; p=0.008) as a significant risk factor for side effects during VIT in children. Conclusion Results of our study determined an association between accompanying asthma and side effects during VIT. Patients with asthma may need a particularly high degree of surveillance during VIT procedure.